Epcoritamab vs Rituximab
Epcoritamab vs Rituximab: Overview
This comparison examines the pharmacological differences between Epcoritamab and Rituximab.
Mechanism of Action
Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.
Pharmacokinetics
Half-life: Rituximab β 22 days.
Chemical Properties
Type: Epcoritamab β Antibody; Rituximab β Antibody.